13704 Modulating Toll-like receptors and antimicrobial peptides in atopic dermatitis: Ex vivo and in vivo studies

Abstract

Methods: A) Ex vivo: human normal skin explants (HNSE) were treated by monoclonal antibody anti–Toll-like receptor 2 (MAB-aTLR2) or by an emulsion O/W containing a vegetal complex at 1% (OMBELLIFERAE extract, a lipid and an amide; C1%) or by its vehicle. At 1 h were added S. aureus’ glycopeptides (SaGP). At 24 h were assessed (ELISA) the expressions of interleukin-8 (IL-8) and of human betadefensin-2 (hBD2). B) In vivo: same emulsion was tested in a pilot clinical trial in atopic dermatitis (AD) children, were assessed SCORAD1 and CLQI2.